Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q2 2015 · 10-Q
Revenue—
Net Income-$7.46M-$7.46MN/M vs Q2 2014 EPS Diluted-$0.20-$0.20N/M vs Q2 2014 Operating Income-$7,404,514N/M Operating Cash Flowderived-$5,267,195N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Jun 30, 2015 · filed Aug 7, 2015 · 38 d after period end